Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2877-2880

  Shawar, Ribhi M ^a   MacLeod, David L ^a   Garber, Richard L ^a   Burns, Jane L ^b   Stapp, Jenny R ^b   Clausen, Carla R ^b   Tanaka, S K ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL TRIAL; CYSTIC FIBROSIS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0032804038     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2877     Document Type: Article

References (30)

1. Ansorg, R., K. D. Muller, and J. Wiora. 1990. Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Chemotherapy (Basel) 36: 222-229.
2. Arguedas, A. G., J. C. Akaniro, H. R. Stutman, and M. I. Marks. 1990. In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum. Antimicrob Agents Chemother 34:2223-2227.
3. Baltch, A. L., R. P. Smith, and W. Ritz. 1994. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp. Chemotherapy (Basel) 40:391-398.
4. Bayer, A. S., D. P. Speert, S. Park, J. Tu, M. Wilt, C. C. Nast, and D. C. Norman. 1991. Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polytnorphonuclear leukocyte-mediated killing of Pseudomonas aeruginosa. Infect. Immun. 59:302-308.
5. Burns, J. L., J. Emerson, J. R. Stapp, D. L. Yim, J. Krzewinski, L. Louden, B. W. Ramsey, and C. R. Clausen. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27:158-163.
6. Burns, J. L., J. M. Van Dalfsen, R. M. Shawar, K. L. Otto, R. L. Garber, J. M. Quan, A. B. Montgomery, G. M. Albers, B. W. Ramsey, and A. L. Smith. 1999. Effect of chronic intermittent administration of Inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179:1190-1196.
7. Ciofu, O., B. Giwercman, S. S. Pedersen, and N. Hoiby. 1994. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF center. APMIS 102:674-680.
8. Cystic Fibrosis Foundation. 1994. Microbiology and infectious diseases in cystic fibrosis. Consensus Conference: Concepts in Care, vol. 5. section 1. Cystic Fibrosis Foundation, Bethesda, Md.
9. Cystic Fibrosis Foundation. 1998. Patient registry 1997 annual data report. Cystic Fibrosis Foundation, Bethesda, Md.
10. Dostal, R. E., J. P. Seale, and B. J. Yan. 1992. Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis. Med. J. Aust. 156:20-24.
11. FitzSimmons, S. C. 1993. The changing epidemiology of cystic fibrosis. J. Pediatr 122:1-9.
12. Gerding, D. N., and T. A. Larson. 1986. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985. Am. J. Med. 80(Suppl. 6B):22-28.
13. Gilligan, P. 1995. Pseudomonas and Burkholderia, p. 509-519. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
14. Gordts, B., C. Vandenborre, P. VanderAuwera, and J. P. Butzler. 1984. Comparison between the in-vitro activity of new agents on Pseudomonas aeruginosa isolates from cystic fibrosis patients and other chronic infections. J. Antimicrob. Chemother. 14:25-29.
15. Govan, J. R. W., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.
16. Hurley, J. C., G. H. Miller, and A. L. Smith. 1995. Mechanisms of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Diagn. Microbiol. Infect. Dis. 22:331-336.
17. Iaconis, J. P., D. H. Pitkin, W. Sheikh, and H. L. Nadler. 1997. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin. Infect. Dis. 24(Suppl. 2):S191-S196.
18. Lester, A., and J. J. Andreasen. 1988. In vitro susceptibility of Pseudomonas aeruginosa from bacteremic and fibrocystic patients to four quinolones and live other antipseudomonal antibiotics. Scand. J. Infect. Dis. 20:525-529.
19. McNeill, W. F., J. F. John, and J. A. Twitty. 1984. Aminoglycoside resistance in Pseudomonas aeruginosa isolated from cystic fibrosis patients. Am. J. Clin. Pathol. 81:742-747.
20. Miller, G. H., F. J. Sabatelli, L. Naples, R. S. Hare, and K. J. Shaw. 1995. The most frequently occurring aminoglycoside resistance mechanisms-combined results of surveys in eight regions of the world. J. Chemother. 7:17-30.
21. Miller, G. H., F. J. Sabatelli, R. S. Hare, Y. Glupczynski, P. Mackey, D. Shlaes, K. Shimizu, K. J. Shaw, and the Aminoglycoside Resistance Study Groups. 1997. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin. Infect. Dis. 24:S46-S62.
22. Mouton, J. W., J. G. den Hollander, and A. M. Horrevorts. 1993. Emergence of antibiotic resistance among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J. Antimicrob. Chemother. 31:919-926.
23. National Committee for Clinical Laboratory Standards. 1995. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Ramsey, B. W., M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, M. Vasiljev-K, D. Borowitz, C. M. Bowman, B. C. Marshall, S. Marshall, and A. L. Smith. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 340:23-30.
25. Saiman, L., F. Mehar, W. W. Niu, H. C. Neu, K. J. Shaw, G. Miller, and A. Prince. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537.
26. Shaw, K. J., R. S. Hare, F. J. Sabatelli, M. Rizzo, C. A. Cramer, L. Naples, S. Kocs, H. Munayyer, P. Mann, G. H. Miller, L. Verbist, H. Van Landuyt, Y. Glupczynski, M. Catalano, and M. Woloj. 1991. Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates. Antimicrob. Agents Chemother. 35:2253-2261.
27. Stutman, H. R., J. C. Akaniro, C. E. Vidaurre, and M. I. Marks. 1990. In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum. Antimicrob. Agents Chemother. 34:1366-1370.
28. Taccetti, G., and S. Campana. 1997. Microbiologic data overview of Italian cystic fibrosis patients. Eur. J. Epidemiol. 13:323-327.
29. Thomassen, M. J., C. A. Demko, B. Boxerbaum, R. C. Stern, and P. J. Kuchenbrod. 1979. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J. Infect. Dis. 140:873-880.
30. Toscano, M. A., M. Minneci, M. Salmeri, and G. Nicoletti. 1991. New epidemiological data on resistance to netilmicin and other aminoglycosides. J. Chemother. 3:352-356.